Mylan introduces generic version of Lexapro tablets

Lexapro tablets are used for acute and maintenance treatment of major depressive disorder (MDD) and acute treatment of generalized anxiety disorder (GAD).

Mylan will sell the product exclusively until the expiration of the pediatric exclusivity on the compound patent, according to the settlement agreement between Mylan’s Alphapharm subsidiary and Forest Laboratories.

According to IMS Health, Lexapro had US sales of approximately $2.9bn for the 12 months ending 31 December 2011.

Mylan CEO Heather Bresch said the first equivalent product to Lexapro, allows customers, payors and patients to realize significant savings from the company’s high quality, more affordable treatment option.